Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,